Featured Publications
Babesia duncani, a Model Organism for Investigating Intraerythrocytic Parasitism and Novel Antiparasitic Therapeutic Strategies
Fang T, Mamoun C. Babesia duncani, a Model Organism for Investigating Intraerythrocytic Parasitism and Novel Antiparasitic Therapeutic Strategies. The Journal Of Infectious Diseases 2024, 230: 263-270. PMID: 39052743, PMCID: PMC11272067, DOI: 10.1093/infdis/jiae191.Peer-Reviewed Original ResearchConsequences of malariaDevelopment of future therapiesIntraerythrocytic parasitesHost red blood cellsDrugs in vitroB. duncaniIn vitro culture systemRed blood cellsFuture therapiesTherapeutic strategiesAnimal modelsWell-annotated genomeBlood cellsResistance mechanismsPathological consequencesMode of actionBabesia duncaniCulture systemParasite biologyPathogensMalariaPlasmodiumTherapyAnimalsCulture conditions
2021
Treatment of Human Babesiosis: Then and Now
Renard I, Ben Mamoun C. Treatment of Human Babesiosis: Then and Now. Pathogens 2021, 10: 1120. PMID: 34578153, PMCID: PMC8469882, DOI: 10.3390/pathogens10091120.Peer-Reviewed Original ResearchHuman babesiosisSevere adverse eventsNew therapeutic strategiesPublic health concernTick-borne diseaseAdverse eventsBlood transfusionCombination therapySafe therapyRisk of humanTherapeutic strategiesHuman transmissionApicomplexan parasitesDrug resistanceHealth concernBabesiosisTherapyTreatmentDiseaseCurrent arsenalParasitesRapid emergenceTransfusionClindamycinAzithromycinEffective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection
Chiu JE, Renard I, Pal AC, Singh P, Vydyam P, Thekkiniath J, Kumar M, Gihaz S, Pou S, Winter RW, Dodean R, Frueh L, Nilsen AC, Riscoe MK, Doggett JS, Mamoun C. Effective Therapy Targeting Cytochrome bc1 Prevents Babesia Erythrocytic Development and Protects from Lethal Infection. Antimicrobial Agents And Chemotherapy 2021, 65: 10.1128/aac.00662-21. PMID: 34152821, PMCID: PMC8370247, DOI: 10.1128/aac.00662-21.Peer-Reviewed Original ResearchConceptsEndochin-like quinolonesLethal infectionBlood-borne diseasesBlood-borne pathogensEffective therapyRelated apicomplexan parasitesExperimental therapiesLow doseMouse modelInfectious agentsHuman infectionsInfectionClinical candidatesStrong efficacyB. microtiExcellent safetyMode of actionTherapyErythrocytic developmentAtovaquoneEfficacyApicomplexan parasitesSafetyStructure-activity relationshipsParasitemia